Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Sale
Global Breast Cancer Therapeutics Market Size, Share, Research: By Therapy: Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy; By Cancer Type: Hormone Receptor, HER2+; By Distribution Channel: Hospital Pharmacies, Others; Regional Analysis; Competitive Landscape: Industry Events and Developments; 2023-2028
Global Breast Cancer Therapeutics Market Outlook
The global breast cancer therapeutics market is likely to expand at a CAGR of 10.3% during the period 2023-2028. North America, Europe and Asia are estimated to be significant markets.
Global Market Likely to be Driven by Rising Incidents of Breast Cancer and Developments in Treatment Systems
Breast cancer is common in women across the globe and a major reason of cancer related deaths in women. It has been suggested that in USA, over 250,000 fresh cases of invasive breast cancer would be identified in women in 2022, while over forty thousand women are estimated to die of the disease. Breast cancer generally develops in middle-aged and older women. It is noteworthy that men are also prone to breast cancer, though to a very lesser degree. Continual research has led to significant transformation in breast cancer care; procedures such as mastectomy and chemotherapy, along with developments in screening and diagnosis (mammography) and improved disease awareness have considerably enhanced the chances of survival of people suffering from breast cancer.
Symptoms may include lump or thickening feeling dissimilar to surrounding tissue, changes crusting, peeling, or flaking of the pigmented site around the areola or breast skin, pitting or redness of skin over the breast, and others.
Developments in molecular biology, systems biology and genome sciences have offered a deeper understanding of breast cancer at various levels, including genomic, molecular and cellular. Biologically, breast cancer is one of the several types of tumour with multiple factors driving its progression and development.
Developments in Treatment Systems Expected to Boost Market Growth
Companies seek to enhance outcomes of breast cancer patients through scientific innovations and possible path-breaking medicines. Treatments of breast cancer include chemotherapy, surgery, and therapies including biological, hormonal, and radiation. Drugs that have been approved to treat breast cancer include Abemaciclib, Capecitabine, Doxorubicin Hydrochloride, Epirubicin Hydrochloride, Fareston (Toremifene), Gemzar (Gemcitabine Hydrochloride), Halaven (Eribulin Mesylate), and others. Combinations used to treat breast cancer include AC-T, AC, CMF, CAF, FEC, and TAC.
Key Developments and News
In 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was afforded Breakthrough Therapy Designation in USA for patients with HER2-low metastatic breast cancer. Such developments are likely to stimulate the global breast cancer therapeutics market.
In 2021, Verzenio® (abemaciclib) was approved by the FDA as the initial and lone CDK4/6 inhibitor for individuals with HR+ HER2- high risk early breast cancer.
Market Segmentation
By therapy, the market is segmented into:
- Targeted Therapy (further broken down by type as given below)
- Ado-Trastuzumab Emtansine
- Abemaciclib
- Trastuzumab
- Everolimus
- Palbociclib
- Ribociclib
- Olaparib
- Pertuzumab
- Hormonal Therapy (further broken down by type as given below)
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Estrogen Receptor Downregulators (ERDs)
- Chemotherapy (further broken down by type as given below)
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
- Epothilones
- Immunotherapy
By cancer type, the market is classified into:
- Hormone Receptor
- HER2+
By distribution channel, the market is divided into:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
By region, the market is segmented into:
- Europe
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
Key Industry Players in the Market
The report extensively analyses major players in the global breast cancer therapeutics market, evaluating their capacity and monitoring latest developments like plant turnarounds, capacity expansions, and mergers and acquisitions:
- Eli Lilly and Company
- Genentech, Inc.
- AstraZeneca
- Novartis AG
- Sanofi
- Others
The EMR report offers deep industry insights through a SWOT analysis and Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy |
|
| Breakup by Cancer Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Breast Cancer Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Breast Cancer Therapeutics Historical Market (2018-2022)
8.3 Global Breast Cancer Therapeutics Market Forecast (2023-2028)
8.4 Global Breast Cancer Therapeutics Market by Therapy
8.4.1 Targeted Therapy
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.1.4 Breakup by Type
8.4.1.4.1 Abemaciclib
8.4.1.4.2 Ado-Trastuzumab Emtansine
8.4.1.4.3 Everolimus
8.4.1.4.4 Trastuzumab
8.4.1.4.5 Ribociclib
8.4.1.4.6 Palbociclib
8.4.1.4.7 Pertuzumab
8.4.1.4.8 Olaparib
8.4.2 Hormonal Therapy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.2.4 Breakup by Type
8.4.2.4.1 Selective Estrogen Receptor Modulators (SERMs)
8.4.2.4.2 Aromatase Inhibitors
8.4.2.4.3 Estrogen Receptor Downregulators (ERDs)
8.4.3 Chemotherapy
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.3.4 Breakup by Type
8.4.3.4.1 Taxanes
8.4.3.4.2 Anthracyclines
8.4.3.4.3 Anti-metabolites
8.4.3.4.4 Alkylating Agents
8.4.3.4.5 Epothilones
8.4.4 Immunotherapy
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.5 Global Breast Cancer Therapeutics Market by Cancer Type
8.5.1 Hormone Receptor
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 HER2+
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.6 Global Breast Cancer Therapeutics Market by Distribution Channel
8.6.1 Hospital Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Retail Pharmacies
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Online Pharmacies
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.6.4 Others
8.7 Global Breast Cancer Therapeutics Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Genentech, Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Eli Lilly and Company
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Novartis AG
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 AstraZeneca
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Sanofi
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Breast Cancer Therapeutics Market: Key Industry Highlights, 2018 and 2028
2. Global Breast Cancer Therapeutics Historical Market: Breakup by Therapy (USD Million), 2018-2022
3. Global Breast Cancer Therapeutics Market Forecast: Breakup by Therapy (USD Million), 2023-2028
4. Global Breast Cancer Therapeutics Historical Market: Breakup by Cancer Type (USD Million), 2018-2022
5. Global Breast Cancer Therapeutics Market Forecast: Breakup by Cancer Type (USD Million), 2023-2028
6. Global Breast Cancer Therapeutics Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
7. Global Breast Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
8. Global Breast Cancer Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2022
9. Global Breast Cancer Therapeutics Market Forecast: Breakup by Region (USD Million), 2023-2028
10. North America Breast Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
11. North America Breast Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Europe Breast Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
13. Europe Breast Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Asia Pacific Breast Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
15. Asia Pacific Breast Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Latin America Breast Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
17. Latin America Breast Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Middle East and Africa Breast Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
19. Middle East and Africa Breast Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Global Breast Cancer Therapeutics Market Structure
Key Questions Answered in the Report
The global breast cancer therapeutics market is estimated to grow at a CAGR of 10.3% between 2023 and 2028.
The major market drivers are technological advancements and the growing incidence of breast cancer.
The key market trends include increasing investments in research and development, coupled with the launch of several diagnostic and screening programs.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The various therapies of breast cancer therapeutics in the market include targeted therapy, hormonal therapy, and chemotherapy.
The various cancer types of breast cancer therapeutics in the market include hormone receptor and HER2+.
The various distribution channels of breast cancer therapeutics in the market include retail pharmacies, hospital pharmacies, and online pharmacies, among others.
The major players in the market are Eli Lilly and Company, Genentech, Inc., AstraZeneca, Novartis AG, and Sanofi, among others.
Breast cancer is a known as a disease in which cells in the breast grow out of control.
Women who have inherited changes also known as mutations to specific genes, like BRCA1 and BRCA2, are at higher risk of breast and ovarian cancer.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$3199$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$4199$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$5199$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER